top of page

Lab of Neurologic recovery & Rejuvenation
소영 정
편집자
운영자
더보기
프로필
가입일: 2025년 5월 19일
게시물 (24)
2026년 10월 13일 ∙ 2 분
The STELLAR trial: a phase II/III randomized trial of high-dose, intermittent sunitinib in patients with recurrent glioblastoma
Jorien B E Janssen 1,#, Cyrillo G Brahm 2,#, Chantal M L Driessen 3, Janine Nuver 4, Mariette Labots 5, Mathilde C M Kouwenhoven 6, Esther Sanchez Aliaga 7, Roelien H Enting 8, Jan Cees de Groot 9, Annemiek M E Walenkamp 10, Myra E van Linde 11, Henk M W Verheul 12,13,✉ Brain Commun. 2024 Jul 30;6(4):fcae241. doi: 10.1093/braincomms/fcae241 Abstract Previously, the tyrosine kinase inhibitor sunitinib failed to show clinical benefit in patients with recurrent glioblastoma. Low...
1
0
2026년 9월 15일 ∙ 3 분
Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N2M2 umbrella trial
Wolfgang Wick 1, Lisa-Marie Lanz 2, Antje Wick 3, Inga Harting 4, Susan Dettmer 2, Abigail K Suwala 5, Ralf Ketter 6, Ghazaleh Tabatabai 7 8, Corinna Seliger 3 9, Martin Glas 10, Michael C Burger 11, Marco Timmer 12, Florian A Ringel 13 14, Iris Mildenberger 15 16, Walter J Schulz-Schaeffer 17, Frank Winkler 3, Laila König 18, Christel Herold-Mende 19, Andreas Eisenmenger 2, Stefan M Pfister 20, Mirjam Renovanz 7 8 21, Martin Bendszus 4, Felix Sahm 22, Michael Platten 15 16, Tobias Kessler 3...
7
0
2026년 8월 18일 ∙ 3 분
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial
Patrick Y. Wen, MD1 ; Donald A. Berry, PhD2 ; Meredith B. Buxton, PhD3 ; Howard Colman, MD, PhD, FAAN4 ; John de Groot, MD5 ; Michael Lim, MD6 ; Ingo Mellinghoff, MD7 ; James R. Perry, MD, FRCPC, FAAN8 ; Michael Weller, MD9 ; Nicholas A. Blondin, MD10; Omar H. Butt, MD, PhD, MS11 ; Denise M. Damek, MD12; Macarena I. de la Fuente, MD13 ; Jan Drappatz, MD14; Erin Dunbar, MD15; Pierre Giglio, MD16; Emma Viktoria Hyddmark, PhD3 ; Fabio Iwamoto, MD17; Kurt A. Jaeckle, MD18 ; Lyndon Kim, MD19;...
2
0
bottom of page